Znaczna poprawa stanu zdrowia dziewczynki z deficytem CDKL5 leczonej ganaksolonem i fenfluraminem - opis przypadku

PubMed➕ 20.11.2026Cureus

Marked Improvement in Epilepsy, Movement Disorder and Behaviour in a Child With CDKL5 Deficiency Disorder Treated With Ganaxolone and Fenfluramine: A Case Report

W skrócie

Artykuł opisuje dziewczynkę z rzadką, poważną chorobą mózgu (deficyt CDKL5), która powoduje trudne do opanowania napady padaczki i problemy w rozwoju. Po podaniu dwóch leków - ganaksolonu i fenfluraminu - u dziewczynki zmniejszyła się liczba napadów, była bardziej czujna i lepiej się komunikowała. Połączenie tych leków było dobrze tolerowane i mogło poprawić nie tylko kontrolę napadów, ale także ogólną jakość życia.

Oryginalny abstract (angielski)

CDKL5 deficiency disorder (CDD) is a severe developmental and epileptic encephalopathy characterised by early-onset, treatment-resistant seizures and severe neurodevelopmental impairment. Ganaxolone is approved for the treatment of seizures associated with CDD, while fenfluramine has shown potential antiseizure activity in a small series of patients with CDD. We report the case of a girl with CDD who experienced a marked and partially sustained clinical response to combination therapy with ganaxolone and fenfluramine. Ganaxolone reduced major motor seizure frequency by approximately 50-60%, with additional improvements in alertness, responsiveness, mood, communication and motor development. Following the addition of fenfluramine, motor seizures ceased for eight weeks before recurring at a lower frequency after a febrile illness. Overall, combination therapy was generally well tolerated, although dose escalation was limited by somnolence, which resolved promptly following dose reduction. Serial echocardiograms remained normal. Complete long-term seizure control and EEG normalisation were not achieved. This case suggests that combined ganaxolone and fenfluramine therapy may provide benefits beyond seizure reduction in CDD, including improvements in development, behaviour and overall quality of life, and warrants further investigation.

Metadane publikacji

Journal
Cureus
Data publikacji
01.11.2026
PMID
43061504
DOI
10.7759/cureus.119576
Autorzy
Neubauer BA, Spors H
Słowa kluczowe
case report, cdd, cdkl5 deficiency disorder, developmental epileptic encephalopathy, drug-resistant epilepsy, epilepsy, fenfluramine, ganaxolone
Źródło
PubMed